Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Terns Pharmaceuticals stock

Own Terns Pharmaceuticals stock in just a few minutes.

Terns Pharmaceuticals, Inc is a biotechnology business based in the US. Terns Pharmaceuticals shares (TERN) are listed on the NASDAQ and all prices are listed in US Dollars. Terns Pharmaceuticals employs 30 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Terns Pharmaceuticals

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – TERN – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Terns Pharmaceuticals share price

Use our graph to track the performance of TERN stocks over time.

Terns Pharmaceuticals shares at a glance

Information last updated 2021-04-21.
52-week range$14.83 - $28.36
50-day moving average $21.28
200-day moving average $21.12
Wall St. target price$29.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) N/A

Buy Terns Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Terns Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Terns Pharmaceuticals financials

Gross profit TTM $0
Return on assets TTM -39.83%
Return on equity TTM -68.73%
Profit margin 0%
Book value N/A
Market capitalisation $455.3 million

TTM: trailing 12 months

Shorting Terns Pharmaceuticals shares

There are currently 1.5 million Terns Pharmaceuticals shares held short by investors – that's known as Terns Pharmaceuticals's "short interest". This figure is 70.7% up from 897,027 last month.

There are a few different ways that this level of interest in shorting Terns Pharmaceuticals shares can be evaluated.

Terns Pharmaceuticals's "short interest ratio" (SIR)

Terns Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Terns Pharmaceuticals shares currently shorted divided by the average quantity of Terns Pharmaceuticals shares traded daily (recently around 226784.44444444). Terns Pharmaceuticals's SIR currently stands at 6.75. In other words for every 100,000 Terns Pharmaceuticals shares traded daily on the market, roughly 6750 shares are currently held short.

To gain some more context, you can compare Terns Pharmaceuticals's short interest ratio against those of similar companies.

However Terns Pharmaceuticals's short interest can also be evaluated against the total number of Terns Pharmaceuticals shares, or, against the total number of tradable Terns Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Terns Pharmaceuticals's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Terns Pharmaceuticals shares in existence, roughly 60 shares are currently held short) or 0.1126% of the tradable shares (for every 100,000 tradable Terns Pharmaceuticals shares, roughly 113 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Terns Pharmaceuticals.

Find out more about how you can short Terns Pharmaceuticals stock.

Terns Pharmaceuticals share dividends

We're not expecting Terns Pharmaceuticals to pay a dividend over the next 12 months.

Have Terns Pharmaceuticals's shares ever split?

Terns Pharmaceuticals's shares were split on a 1000:50 basis on 3 November 2013. So if you had owned 50 shares the day before before the split, the next day you'd have owned 1000 shares. This wouldn't directly have changed the overall worth of your Terns Pharmaceuticals shares – just the quantity. However, indirectly, the new 95% lower share price could have impacted the market appetite for Terns Pharmaceuticals shares which in turn could have impacted Terns Pharmaceuticals's share price.

Terns Pharmaceuticals overview

Terns Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and other chronic liver diseases. It develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase I clinical trial for the treatment of NASH. The company also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and GLP-1R, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to address metabolic processes involved in the pathogenesis of NASH. Terns Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Foster City, California. .

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site